Baillie Gifford & CO Cellectis S.A. Put Options Transaction History
Baillie Gifford & CO
- $126 Billion
- Q1 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding CLLS
# of Institutions
31Shares Held
9.83MCall Options Held
0Put Options Held
30.9K-
Long Focus Capital Management, LLC San Juan, PR4.49MShares$9.15 Million0.64% of portfolio
-
Capital International Investors Los Angeles, CA1.85MShares$3.77 Million0.0% of portfolio
-
Credit Suisse Ag Zurich, V81.44MShares$2.93 Million0.0% of portfolio
-
Principal Financial Group Inc Des Moines, IA425KShares$866,0470.0% of portfolio
-
Macquarie Group LTD Australia, C3227KShares$462,8250.0% of portfolio
About Cellectis S.A.
- Ticker CLLS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 45,510,800
- Market Cap $92.8M
- Description
- Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatm...